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Preoperative intravenous iron to treat anaemia before 
major abdominal surgery (PREVENTT): a randomised, 
double-blind, controlled trial
Toby Richards, Ravishankar Rao Baikady, Ben Clevenger, Anna Butcher, Sandy Abeysiri, Marisa Chau, Iain C Macdougall, Gavin Murphy, 
Rebecca Swinson, Tim Collier, Laura Van Dyck, John Browne, Andrew Bradbury, Matthew Dodd, Richard Evans, David Brealey, Stefan D Anker, 
Andrew Klein
Summary
Background Preoperative anaemia affects a high proportion of patients undergoing major elective surgery and is 
associated with poor outcomes. We aimed to test the hypothesis that intravenous iron given to anaemic patients 
before major open elective abdominal surgery would correct anaemia, reduce the need for blood transfusions, and 
improve patient outcomes.
Methods In a double-blind, parallel-group randomised trial, we recruited adult participants identified with anaemia 
at preoperative hospital visits before elective major open abdominal surgery at 46 UK tertiary care centres. 
Anaemia was defined as haemoglobin less than 130 g/L for men and 120 g/L for women. We randomly allocated 
participants (1:1) via a secure web-based service to receive intravenous iron or placebo 10–42 days before surgery. 
Intravenous iron was administered as a single 1000 mg dose of ferric carboxymaltose in 100 mL normal saline, 
and placebo was 100 mL normal saline, both given as an infusion over 15 min. Unblinded study personnel 
prepared and administered the study drug; participants and other clinical and research staff were blinded to 
treatment allocation. Coprimary endpoints were risk of the composite outcome of blood transfusion or death, and 
number of blood transfusions from randomisation to 30 days postoperatively. The primary analysis included all 
randomly assigned patients with data available for the primary endpoints; safety analysis included all randomly 
assigned patients according to the treatment received. This study is registered, ISRCTN67322816, and is closed to 
new participants.
Findings Of 487 participants randomly assigned to placebo (n=243) or intravenous iron (n=244) between Jan 6, 2014, 
and Sept 28, 2018, complete data for the primary endpoints were available for 474 (97% ) individuals. Death or blood 
transfusion occurred in 67 (28%) of the 237 patients in the placebo group and 69 (29%) of the 237 patients in the 
intravenous iron group (risk ratio 1·03, 95% CI 0·78–1·37; p=0·84). There were 111 blood transfusions in the placebo 
group and 105 in the intravenous iron group (rate ratio 0·98, 95% CI 0·68–1·43; p=0·93). There were no significant 
differences between the two groups for any of the prespecified safety endpoints.
Interpretation Preoperative intravenous iron was not superior to placebo to reduce need for blood transfusion when 
administered to patients with anaemia 10–42 days before elective major abdominal surgery.
Funding UK National Institute of Health Research Health Technology Assessment Program.
Copyright 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Preoperative anaemia affects 30–60% of all patients 
undergoing major elective surgery and is associated with 
an increased risk of blood transfusion, in-hospital 
complications, delayed hospital discharge, and poor 
recovery.1,2 The commonest cause of anaemia is iron 
deficiency, either due to nutritional deficiency or blood 
loss leading to a state of absolute iron deficiency charac-
terised by low iron stores. Surgical patients often have 
inflammation or chronic diseases that cause disruptions 
to the normal pathways for iron transport and iron 
metabolism. Specifically, the master regulator of iron 
meta bolism, hepcidin, is elevated, which inhibits 
iron transport out of cells. This process prevents dietary 
iron absorption and promotes sequestering of avail-
able iron into macrophages, leading to a state of func-
tional iron deficiency that in turn leads to anaemia of 
chronic disease.3–5 Consequently, treatment of anaemic 
surgical patients with oral iron is considered ineffective.6
In contrast, the use of intravenous iron bypasses 
these hepcidin-mediated pathways and can result in 
improvements in haemoglobin concentration, functional 
performance, and quality of life in patients with anaemia 
of chronic disease seen with kidney failure,7 heart failure,8 
inflammatory bowel disease,9 and women’s health.10,11
International treatment guidelines recommend that 
patients undergoing surgery with an expected blood loss 
of 500 mL or more should be screened for anaemia at 
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least 2 weeks before surgery, with a recommendation 
that anaemia should be treated with intravenous iron.12,13 
However, the diagnosis of iron deficiency in patients 
with preoperative anaemia is not clear and the use of 
intravenous iron in patients before surgery to correct 
anaemia and reduce blood transfusion is based on very 
low-quality evidence.14 To address this knowledge gap, 
we conducted a double-blind, placebo-controlled, ran-
domised trial to compare the clinical effectiveness of 
intravenous iron therapy given to patients with anaemia 
10–42 days before major open elective abdominal 
surgery. We hypothesised that intravenous iron would 
be superior to placebo with respect to patient outcomes 
of blood transfusion, death, adverse events, and quality 
of life.
Methods
Study design and participants
Preoperative intravenous iron to treat anaemia in major 
surgery (PREVENTT) was a multicentre, double-blind, 
parallel-group, randomised study in adult patients 
identified with anaemia 10–42 days before major open 
abdominal surgery at 46 UK tertiary care centres. The 
original study protocol is available online and methodo-
logical details of the trial are presented in the appendix 
and described in brief here. The trial was approved by 
the UK National Research Ethics Committee, East of 
England.
Eligible participants, identified in preoperative hos-
pital visits, were older than 18 years of age and had 
haemoglobin less than 130 g/L for men and 120 g/L for 
women. Specific iron studies were not part of the primary 
inclusion criteria but formed part of the predefined 
subgroup analysis. Major surgery was defined as surgery 
lasting more than 1 h with an operative code of major, 
major plus, or complex major operation. Exclusions 
included laparoscopic surgery, concurrent infection, 
bodyweight of less than 50 kg, known chronic liver 
disease, another cause for anaemia (eg, haemo-
globinopathy) or acquired iron overload, known family 
history of haemochromatosis or thalassaemia, or trans-
ferrin saturation greater than 50%. Full eligibility criteria 
is included in the appendix (p 6). Participants provided 
written informed consent.
Randomisation and masking
Randomisation was done by trained staff members using 
a secure web-based service through the Clinical Trials Unit 
at the London School of Hygiene & Tropical Medicine. The 
web-based service was provided by an indepen dent 
research support organisation. Ran domisation was 1:1, 
with allocation concealment that used minimisation, 
considering baseline haemoglobin (<100 vs ≥100 g/L), age 
(<70 vs ≥70 years), centre, and operation type (major, major 
plus, complex major). Because the intravenous iron was a 
dark-brown solution that is easily distinguishable from 
Research in context
Evidence before this study
Preoperative anaemia is common in surgical patients and 
associated with worse patient outcomes including increased 
need for blood transfusion, postoperative complications, 
and longer hospital stay. The commonest cause is iron 
deficiency due to blood loss from the underlying disease for 
which the patient is having surgery (eg, gastrointestinal cancer) 
or indirectly due to inflammation from the disease process or 
secondary to patient comorbidities that disrupt iron absorption 
and iron transport leading to anaemia of chronic disease. In the 
preoperative setting, oral iron has a limited role as the 
absorption is blocked and there is little time before surgery to 
replenish iron stores. Intravenous iron has been proposed as an 
alternative owing to its ability to bypass normal iron transport 
pathways and deliver a large dose of iron directly to the bone 
marrow to treat anaemia.
The National Health Service (NHS) England Commissioning for 
Quality and Innovation scheme for 2020–21 recommends that 
patients undergoing surgery with an expected blood loss of 
500 mL or more should be screened for anaemia at least 
2 weeks before surgery and treated with iron therapy if 
necessary. The guidance claims that “Improved compliance 
would reduce blood transfusion rate for major blood loss 
surgeries, reducing the occurrence of patient safety risks 
associated with blood transfusion including fluid overload, 
infection and incorrect blood transfusions being given.” 
However, this is based on guidance from the UK’s National 
Institute for Health and Care Excellence (NICE) that reported 
only very low quality of evidence.
A Cochrane review of iron therapy for preoperative anaemia 
was updated in December, 2019. This review concluded that the 
use of iron therapy for preoperative anaemia does not show a 
clinically significant reduction in allogeneic blood transfusion 
compared with no iron therapy but that further, well designed, 
adequately powered, randomised controlled trials were 
required to determine the true effectiveness of iron therapy for 
preoperative anaemia.
Added value of this study
The primary results of our trial show no evidence of clinical 
benefit in giving intravenous iron preoperatively to patients 
undergoing major abdominal surgery and provide the highest 
quality of evidence to date, with sufficient statistical power to 
make strong inferences about effectiveness.
Implications of all the available evidence
The evidence base now suggests that current guidance on 
preoperative iron therapy by, for example, NHS England and 
NICE, should be revised and now state that preoperative iron 
therapy is not recommended in major elective surgery patients 
with anaemia.
For more on operative codes see 
https://www.ccsd.org.uk/home
For the study protocol see 
https://preventt.lshtm.ac.uk/
protocol-3/
See Online for appendix
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the saline placebo, dedicated unblinded study personnel 
were responsible for the preparation and administration 
of the study drug but had no other involvement in the 
trial. To ensure blinding of the participants, their skin 
was swabbed with iodine, and the study treatment was 
shielded from vision (light protection bags) and infused 
through black tubing. Other clinical and research staff 
were blinded to the treatment allocated.
Procedures
Intravenous iron was administered as a single 1000 mg 
dose of ferric carboxymaltose (Ferinject, Vifor Pharma 
Management, Zurich, Switzerland) in 100 mL normal 
saline, and placebo was 100 mL normal saline, both given 
as an infusion over 15 min. Participants were monitored 
for adverse events or signs of hypersensitivity during 
and for at least 30 min after treatment. There was no 
other change to the patient’s normal surgical pathway. 
Clinical assessments and patient-reported outcomes were 
recorded at enrol ment, during the index hospital admis-
sion, and 8 weeks and 6 months after the index surgery.
Outcomes
The trial had two coprimary outcomes: risk of the 
composite endpoint of blood transfusion or death and 
the number of blood transfusion episodes from ran-
domisation until 30 days after the index operation. 
A blood transfusion was defined as receiving 1 unit 
(or part thereof) of packed red blood cells or any other 
blood component. A blood transfusion episode referred 
to the administration of 1 or more units of packed red 
blood cells or any other blood components in one 24-h 
period and a large transfusion where 4 or more blood 
transfusions were given in one episode.
Secondary endpoints included: total number of units of 
packed red blood cells or blood components transfused 
(excluding large blood transfusions) at 30 days and 
6 months after surgery, change in haemoglobin concen-
tration from randomisation to day of the index operation 
(before surgery) and at 8 weeks and 6 months after 
surgery, postoperative complications, intensive care unit 
(ICU) and total hospital length of stay, days alive and out 
of the hospital from the date of the planned surgery until 
30 days after the index operation, readmission to the 
hospital at 8 weeks and 6 months postoperatively, and 
health-related quality of life (HRQoL). Haemoglobin at 
baseline (pre-randomised treatment) and on the day of 
the index operation (before surgery) were measured by a 
central laboratory; all other measurements were from 
local laboratories. Local sites were responsible for data 
collection. De-identified data were adjudicated centrally 
before data lock and unblinding for analysis. HRQoL was 
measured by the Multidimen sional Fatigue Inventory 
(MFI) questionnaire15 and the European Quality of Life: 
5 Dimensions 5 Levels (EQ-5D-5L)16 score on the day of 
the index operation (before surgery) and 8 weeks and 
6 months after the index operation (appendix pp 7–8).
Prespecified safety endpoints were serious adverse 
events, suspected unexpected serious adverse events, 
adverse reactions to trial therapy, and development of 
perioperative acute kidney injury. All serious adverse 
events were reviewed by one of the research fellows 
(BC, AB, or SA) and then adjudicated and coded by 
LVD using standard Medical Dictionary of Regulatory 
Authorities (MedDRA). The MedDRA codes were then 
checked by the research fellows. All reviews were carried 
out blinded to the treatment.
Statistical analysis
Assuming an anticipated blood transfusion risk of 
40% in the placebo group, we calculated that 500 patients 
Figure 1: Trial profile
ITT=intention-to-treat. IV=intravenous. *Patient had blood transfusion before withdrawal or loss to follow-up and 
is therefore included in analysis of the coprimary endpoints.
487 patients randomised 
243 assigned to placebo
241 treated
2 not treated 
228 surgery took place
13 surgery cancelled
238 patients at 8-week visit 234 patients at 8-week visit
226 patients at 6-month visit








1 lost to follow-up
1 withdrew*
2 lost to follow-up*
7 deaths
2 deaths
1 lost to follow-up*
5 deaths
244 assigned to IV iron
240 treated
4 not treated
233 surgery took place
10 surgery cancelled
226 patients at 6-month visit
237 included in ITT analysis for 
coprimary endpoints
1 withdrew
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would provide 90% power at the 5% significance level to 
detect an absolute reduction of 14% for the composite 
coprimary endpoint of blood transfusion or death by 
30 days after the surgery, allowing for 5% loss to 
follow-up.
The primary analysis was by intention to treat, including 
all randomly assigned patients with data available for the 
primary endpoints; safety analysis included all randomly 
assigned patients according to the treatment received. 
For the first coprimary endpoint, a risk ratio and 95% CI 
were calculated using binomial regression, and a p value 
was calculated using a likeli hood ratio test. For the 
second coprimary endpoint, a rate ratio and 95% CI were 
calculated using a negative binomial regression model, 
and a likelihood ratio test p value was calculated. Because 
some patients died before the end of the study, the length 
of each patient’s period of observation was included as an 
exposure in the model. To account for multiple testing, a 
Benjamini–Hochberg procedure with a 5% false discovery 
rate was used to determine statistical significance for 
the coprimary endpoints.17 The analysis of the coprimary 
endpoints was repeated for the per-protocol population, 






Age (years) 65 (50–72) 66 (57–72)
Men 101 (42%) 119 (49%)
Women 142 (58%) 125 (51%)
Ethnicity
White 217 (89%) 211 (86%)
Afro-Caribbean 19 (8%) 14 (6%)
Asian 6 (2%) 18 (7%)
Other 1 (<1%) 1 (<1%)
Haemoglobin (g/L)
<90 6 (2%) 7 (3%)
90–99 36 (15%) 35 (14%)
100–109 64 (26%) 55 (23%)
110–119 71 (29%) 80 (33%)
≥120 57 (23%) 61 (25%)
Clinical measures
American Society of Anesthesiologists grade
I 31 (13%) 30 (12%)
II 141 (58%) 147 (60%)
III 65 (27%) 56 (23%)
IV 1 (<1%) 1 (<1%)
Missing 5 (2%) 10 (4%)
Medical history
Acid reflux or stomach ulcer 54 (22%) 54 (22%)
Angina or chest pain 16 (7%) 15 (6%)
Bleeding tendencies 7 (3%) 11 (5%)
Breathlessness 28 (12%) 25 (10%)
Coeliac disease 2 (1%) 0
COPD, bronchitis, or asthma 37 (15%) 27 (11%)
Stroke or transient ischaemic 
attack
13 (5%) 4 (2%)
Diabetes 38 (16%) 37 (15%)
Inflammatory bowel disease 13 (5%) 13 (5%)
Iron deficiency 69 (28%) 70 (29%)
Heart failure 3 (1%) 9 (4%)
Hiatus hernia 23 (9%) 17 (7%)
Hypertension 93 (38%) 89 (36%)
Kidney or urinary problems 37 (15%) 39 (16%)
Liver disease 8 (3%) 14 (6%)
Myocardial infarction 20 (8%) 12 (5%)
Rheumatoid arthritis 12 (5%) 10 (4%)
Preoperative chemotherapy 59 (24%) 50 (20%)
Radiotherapy 6 (2%) 7 (3%)





(Continued from previous column)
Smoking history
Never 116 (48%) 113 (46%)
Former 107 (44%) 108 (44%)
Current 19 (8%) 22 (9%)
Missing 1 (<1%) 1 (<1%)
Current medication that affects bleeding
Aspirin 28 (12%) 23 (9%)
Clopidogrel 5 (2%) 3 (1%)
Other 25 (10%) 22 (9%)
Warfarin 4 (2%) 7 (3%)
Iron tablets
Taking iron tablets 49 (20%) 46 (19%)
Missing 0 1 (<1%)
Planned type of surgery
Complex major operation 85 (35%) 89 (36%)
Major 89 (37%) 87 (36%)
Major plus 69 (28%) 68 (28%)
Surgical details
Surgery took place 228 (94%) 233 (95%)
Time from treatment to surgery
Median (days)* 15 (12–22) 14 (12–21)
<10 days 5 (2%) 8 (3%)
>42 days 21 (9%) 12 (5%)
Type of operation
Abdominal aortic aneurysm 4 (2%) 1 (<1%)
Colorectal 33 (14%) 38 (16%)
General 17 (7%) 21 (9%)
Gynaecological 75 (31%) 63 (26%)
Upper gastrointestinal 77 (32%) 81 (33%)
Urological 22 (9%) 29 (12%)
Anaesthetic time (min) 240 (161–320) 268 (180–376)
Surgery time (min) 145 (98–230) 179 (123–323)
 Data are n (%) or median (IQR) . COPD=chronic obstructive pulmonary disease. 
*Range 6–207 for placebo and 5–212 days for intravenous iron groups.
Table 1: Baseline characteristics and surgical characteristics in PREVENTT
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or undergo surgery, had their operation outside the 
prescribed timelines, had an operation not classified as 
major open abdominal surgery, or withdrew consent. The 
analysis of the two coprimary endpoints was repeated, 
adjusting for variables included in the strati fication for 
randomisation (age, baseline haemoglobin, and planned 
operation type) and from baseline to 6 months after the 
index operation as secondary endpoints.
Haemoglobin concentration was analysed using 
analysis of covariance (ANCOVA), adjusting for baseline 
haemoglobin (appendix p 7). Total number of units 
of blood or blood components (excluding large blood 
transfusions) and number of hospital read missions for 
complications (including repeat readmis sions) were 
analysed using negative binomial regression. ICU length 
of stay, total hospital length of stay, and days alive and out 
of the hospital were analysed using linear regression. 
HRQoL outcomes (MFI and EQ-5D-5L) were analysed 
using ANCOVA adjusting for baseline measurements. 
All-cause mortality, postoperative com plications, and 
read mission to hospital for complications were analysed 
using the same method as for the first coprimary end-
point. Predefined subgroup analyses for the coprimary 
endpoints were done for age (<70 vs ≥70 years), sex (male 
vs female), body-mass index (<30 vs ≥30 kg/m²), operation 
type (major, major plus, or complex major), haemoglobin 
concentration (<100 vs ≥100 g/L), ferritin concentration 
(<100 vs ≥100 ng/mL), and transferrin saturation 
(<20% vs ≥20%). Subgroup analyses were considered 
supplementary and were not adjusted for multiple 
testing. More details of the statis tical methods are 
provided in the clinical trial protocol and the statistical 
analysis plan. All analyses were done with Stata software 
version 15.0. The trial was registered, ISRCTN67322816.
Role of the funding source
The study sponsors had no role in the study design, the 
collection, analysis, and interpretation of data, the writing 
of the report or in the decision to submit the paper for 
publication. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
We recruited 487 participants across 46 UK sites from 
Jan 6, 2014, to Sept 28, 2018 (appendix p 2–5), of whom 
243 were randomly assigned to receive placebo and 
244 to receive intravenous iron (figure 1). Six patients 
did not receive their intended randomised treatment 
(two assigned to placebo, four to intravenous iron). 
Eight patients withdrew consent (four in each group), of 
whom three withdrew between treatment and surgery, 
three between surgery and the 8-week visit, and 
two between the 8-week and 6-month visits. 23 patients 
did not undergo their planned surgery (13 placebo, ten 
intra venous iron), not including the three patients who 
had withdrawn consent before surgery. 46 patients 
had their surgery outside the prescribed timelines 
(26 placebo, 20 intravenous iron), and 20 patients did 
not have major open abdominal surgery (12 placebo, 
eight intravenous iron). For the coprimary endpoints, 
474 (97%) patients were included in the intention-to-
treat analysis and 388 (80%) patients were included in 
the per-protocol analysis.
The participants were well matched regarding base-
line characteristics (table 1). The median age was 66 
(IQR 54–72) years, and 267 (55%) were women. Most were 
American Society of Anesthesiologists grade II (61%) or III 
(26%). Comorbidities included hypertension (182 pa tients, 





Iron vs placebo (95% CI, 
p value)
Blood transfusion or death
Combined 67/237 (28%) 69/237 (29%) 1·03 (0·78–1·37, p=0·84)
Transfusion 67/237 (28%) 68/237 (29%) ··
Death 2/237 (1%) 2/237 (1%) ··
Transfusion episodes
0 170/237 (72%) 169/237 (71%) ··
1 37/237 (16%) 49/237 (21%) ··
2 22/237 (9%) 9/237 (4%) ··
3 5/237 (2%) 5/237 (2%) ··
4 1/237 (<1%) 3/237 (1%) ··
5 1/237 (<1%) 1/237 (<1%) ··
6 1/237 (<1%) 1/237 (<1%) ··
Mean 0·47 (0·9) 0·44 (0·9) 0·98 (0·68–1·43, p=0·93)
Data are n/N (%), mean (SD), and risk or rate ratio (95% CI, p value). A transfusion episode is defined as receiving any 
volume of 1 unit (or part thereof) or more of packed red blood cells or any other blood product. Treatment effect is a risk 
ratio for the first coprimary endpoint (number of blood transfusions or deaths) and a rate ratio for the second coprimary 
endpoint; for the second coprimary endpoint, number of blood transfusions is the number of separate transfusions 
administered.
Table 2: PREVENTT coprimary endpoints from randomisation to 30 days after operation
Figure 2: Mean haemoglobin concentrations of the trial participants by randomised treatment group
Error bars show 95% CI. BL=baseline prerandomised treatment. OP=day of operation before surgery. D=day post 
operation (eg, D2–3=day 2 or 3 post operation). D2–3, D4–5, D6–7, and D14 measurements are only available for 
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infarction (32 patients, 7%), stroke or tran sient ischaemic 
attack (17 patients, 3%), renal disorders (76 patients, 16%), 
and respiratory problems (ie, breath lessness, chronic 
obstructive pulmonary dis ease, bron chitis, or asthma; 
100 patients, 21%). Approxi mately half had never smoked 
and 41 (8%) of 487 patients were current smokers. Known 
iron deficiency and predisposing factors for iron deficiency 
were similar in the two groups.
Of the 487 patients randomly assigned, 461 (95%) 
underwent surgery—228 in the placebo group and 
233 in the intravenous iron group. The median time 
from randomisation to surgery was 15 (IQR 12–22) days 
and was similar in the two groups. The groups were 
well balanced in terms of surgical complexity, with the 
most common operations being upper gastrointes-
tinal (34%), gynaecological (30%), and colorectal (15%). 
At ran domisation, haemoglobin concentrations were 
similar between the placebo (mean 111·0 [SD 11·9] g/L) 
and intravenous iron groups (mean 111·2 [11·8] g/L); 
this significantly increased in the intravenous iron 
group by the time of surgery (mean difference 
[MD] 4·7 g/L, 95% CI 2·7–6·8). Anaemia was corrected 
in 42 (21%) of 244 patients in the intravenous iron 
group compared with 21 (10%) of 243 patients in the 
placebo group (risk ratio 2·06, 95% CI 1·27–3·35). 
Haemoglobin concentrations (figure 2) were not sig nifi-
cantly different in the imme diate postoperative days but 
the intravenous iron group had significantly higher 
haemoglobin concentrations at 8 weeks (MD 10·7 g/L, 
95% CI 7·8–13·7) and at 6 months following interven-
tion (MD 7·3 g/L, 3·6–11·1).
A total of 474 (97%) of 487 patients (237 in each group) 
were included in the intention-to-treat analysis for the 
two coprimary endpoints. Overall, 136 patients (29%) 
received at least one blood transfusion or died between 
ran dom isation and 30 days after the index operation. 
There was no difference between the groups (67 placebo, 
69 intravenous iron; risk ratio 1·03, 95% CI 0·78–1·37; 
p=0·84; absolute risk difference 0·8%, –7·3 to 9·0; 
table 2). 216 transfusion episodes occurred between ran-
domisation and 30 days after the index surgery. There 
was no difference between the groups (111 placebo, 
105 intravenous iron; rate ratio 0·98, 0·68–1·43; p=0·93; 
absolute rate difference 0·00, –0·14 to 0·15; table 2). 
Analysis of the coprimary endpoints at 6 months after 
the index operation also showed no difference between 
the groups (risk ratio for blood transfusion or death 0·99, 
95% CI 0·77–1·28; rate ratio for transfusion episodes 
0·92, 0·64–1·32).
Analyses of the coprimary endpoints adjusting for age, 
sex, body-mass index, operation type, or haemoglobin 
concentration did not change the results (adjusted risk 
ratio for blood transfusion or death to 30 days 1·06, 
95% CI 0·81–1·38; and adjusted rate ratio for transfusion 
episodes 0·99, 0·69–1·42; table 3). Treatment effect 
estimates in the per-protocol analyses were similar (risk 









Blood transfusion or death within 30 days
Age (years)
<70 44/156 (28%) 41/157 (26%) 0·93 (0·64–1·33) ··
≥70 23/81 (28%) 28/80 (35%) 1·23 (0·78–1·95) 0·34
Central laboratory haemoglobin (g/L)
<100 23/42 (55%) 23/41 (56%) 1·02 (0·70–1·51) ··
≥100 44/187 (24%) 45/190 (24%) 1·01 (0·70–1·45) 0·95
Sex
Female 42/139 (30%) 39/122 (32%) 1·06 (0·74–1·52) ··
Male 25/98 (26%) 30/115 (26%) 1·02 (0·65–1·62) 0·91
Body-mass index (kg/m²)
<30 52/178 (29%) 51/161 (32%) 1·08 (0·79–1·50) ··
≥30 15/57 (26%) 18/75 (24%) 0·91 (0·50–1·65) 0·62
Central laboratory ferritin (ng/mL)
<100 34/132 (26%) 34/128 (27%) 1·03 (0·69–1·55) ··
≥100 32/98 (33%) 31/94 (33%) 1·01 (0·67–1·51) 0·94
Central laboratory TSAT (%)
<20 55/174 (32%) 49/163 (30%) 0·95 (0·69–1·31) ··
≥20 8/50 (16%) 15/53 (28%) 1·77 (0·82–3·81) 0·13
Type of surgery
Complex major 25/83 (30%) 20/87 (23%) 0·76 (0·46–1·26) ··
Major 17/86 (20%) 22/85 (26%) 1·31 (0·75–2·29) ··
Major plus 25/68 (37%) 27/65 (42%) 1·13 (0·74–1·73) 0·32
Blood transfusion episodes within 30 days
Age (years)
<70 0·5 (1·0) 0·4 (0·8) 0·79 (0·50–1·24) ··
≥70 0·4 (0·7) 0·6 (1·1) 1·48 (0·79–2·77) 0·11
Central laboratory haemoglobin (g/L)
<100 0·8 (1·1) 0·8 (1·2) 1·07 (0·51–2·24) ··
≥100 0·4 (0·9) 0·4 (0·8) 0·93 (0·61–1·41) 0·74
Sex
Female 0·5 (0·9) 0·4 (0·7) 0·92 (0·55–1·51) ··
Male 0·4 (0·9) 0·5 (1·1) 1·07 (0·61–1·86) 0·69
Body-mass index (kg/m²)
<30 0·5 (0·9) 0·5 (1·0) 1·12 (0·73–1·72) ··
≥30 0·5 (1·0) 0·3 (0·6) 0·68 (0·32–1·42) 0·25
Central laboratory ferritin (ng/mL)
<100 0·5 (1·0) 0·4 (0·9) 0·92 (0·55–1·52) ··
≥100 0·5 (0·8) 0·5 (0·9) 1·07 (0·61–1·88) 0·70
Central laboratory TSAT (%)
<20 0·5 (1·0) 0·5 (1·0) 0·92 (0·60–1·41) ··
≥20 0·3 (0·7) 0·4 (0·7) 1·55 (0·64–3·75) 0·29
Type of surgery
Complex major 0·6 (1·1) 0·4 (1·0) 0·77 (0·43–1·40) ··
Major 0·3 (0·7) 0·3 (0·6) 1·24 (0·62–2·45) ··
Major plus 0·6 (0·9) 0·6 (1·0) 1·09 (0·57–2·08) 0·56
Data are n/N (%), mean (SD), risk or rate ratio (95% CI), or p value. Treatment effect is risk ratio for risk of blood 
transfusion or death within 30 days (first coprimary endpoint) and rate ratio for blood transfusion episodes. 
TSAT=transferrin saturation.
Table 3: Prespecified subgroup analysis for coprimary endpoints
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95% CI 0·77–1·41; and rate ratio for transfusion episodes, 
0·98, 95% CI 0·67–1·44).
Excluding large blood transfusions, 130 patients 
(64 placebo, 66 intravenous iron) were transfused with a 
total of 300 units of blood or blood products between 
randomisation and 30 days after operation. The mean 
transfusion rate at 30 days was 0·65 (SD 1·3) and 
0·61 (1·3) in the placebo and intravenous iron groups, 
respectively (rate ratio 0·98, 95% CI 0·65–1·47; table 4).
At 6 months the overall blood transfusion rate was 29%, 
with 139 of 474 patients receiving at least one transfusion 
from randomisation until 6 months. Overall, packed red 
blood cells were transfused in 133 patients and only 
six patients received a different blood product in isolation; 
three had platelet and three had fresh frozen plasma 
transfusions. Otherwise, blood products were only used 
in combination with packed red cells in the setting of 
large transfusions. The mean transfusion rate was 0·94 
(SD 2·0) and 0·79 (1·6) in the placebo and intravenous 
iron groups, respectively (rate ratio 0·89, 95% CI 
0·60–1·32, p=0·56; table 4).
Postoperative complications were similar in the 
two groups, with 24 (11%) patients in the placebo group 
and 22 (9%) patients in the intravenous iron group 
experiencing significant (defined as Clavien–Dindo 
classi fication grade III or higher) postoperative compli-
cations (risk ratio 0·89, 95% CI 0·52–1·55). There was 
no difference in hospital stay or days alive and out of the 
hospital at 30 days (table 4). Similarly, there were no 
significant between-group differences for any of the 
HRQoL outcomes (table 4).
Readmissions to the hospital following surgery were 
significantly lower in the intravenous iron group in 
the first 8 weeks after the index operation (table 4). 
The number of patients readmitted for postoperative 
complications was 51 (22%) in the placebo group 
versus 31 (13%) in the intravenous iron group (risk 
ratio 0·61, 95% CI 0·40–0·91). Considering repeat 
readmissions, there were a total of 71 readmissions in 
the placebo group compared with 38 in the intravenous 
iron group (rate ratio 0·54, 95% CI 0·34–0·85). The 
most common reasons for readmission at 8 weeks 
were; general postoperative complications (36 [15%] of 
234 patients in the placebo group and 25 [11%] of 
234 patients in the intravenous iron group), general 
infections (seven [3%] in the placebo group and six [3%] 
in the intravenous iron group) and wound infections 
(eight [3%] in the placebo group and one [<1%] in 
the intravenous iron group). At 6 months, there were 
numerically fewer total readmissions in the intravenous 
iron group.
Mortality was similar in the two groups with ten (4%) 
deaths at 6 months in the placebo group and 12 (5%) in 
the intravenous iron group (risk ratio 1·19, 95% CI 
0·52–2·70) and there were no significant differences 






Iron vs placebo 
(95% CI)
Units of blood* transfused from randomisation to 30 days after operation (excluding LBT)
Mean 0·65 (1·3) 0·61 (1·3) 0·98 (0·65 to 1·47)†
Patients with ≥1 transfusion 64/237 (27%) 66/237 (28%) ··
Total units transfused 155 145 ··
Units of blood* transfused from randomisation to 6 months after operation (excluding LBT)
Mean 0·94 (2·0) 0·79 (1·6) 0·89 (0·60 to 1·32)†
Patients with ≥1 transfusion 73/224(33%) 72/220 (33%) ··
Total units transfused 212 174 ··
Days alive and out of hospital within 30 days
Mean 19·8 (7·5) 19·7 (7·0) −0·1 (−1·5 to 1·2)
Postoperative complications
CD grade III or above to discharge 24/227 (11%) 22/233 (9%) 0·89 (0·52 to 1·55)‡
MFI questionnaire
10-day assessment 50·5 (18·9) 53·2 (18·4) 1·2 (−1·1 to 3·4)
8-week assessment 53·9 (17·7) 52·9 (17·1) −1·7 (−4·7 to 1·3)
6-month assessment 47·4 (19·1) 48·8 (18·9) −0·1 (−3·5 to 3·2)
EQ-5D-5L questionnaire
Utility score
10-day assessment 0·81 (0·21) 0·80 (0·20) 0·01 (−0·02 to 0·03)
8-week assessment 0·77 (0·21) 0·79 (0·20) 0·02 (−0·01 to 0·05)
6-month assessment 0·82 (0·21) 0·82 (0·22) 0·02 (−0·02 to 0·05)
Health score
10-day assessment 73·8 (19·6) 70·6 (20·5) −0·8 (−3·5 to 1·9)
8-week assessment 71·1 (19·5) 70·7 (19·4) 0·3 (−3·2 to 3·9)
6-month assessment 76·2 (19·2) 75·0 (18·4) 0·2 (−3·4 to 3·8)
ICU length of stay (days)
Median (IQR) 1 (0–3) 2 (0–3) ··
Range 0–23 0–33 ··
Hospital length of stay (days)
Median (IQR) 9 (5–14) 9 (7–14) ··
Range 1–46 1–118 ··
All-cause mortality
30 days 2/241 (1%) 2/239 (1%) 1·01 (0·14 to 7·10)‡
6 months 10/236 (4%) 12/238 (5%) 1·19 (0·52 to 2·70)‡
Readmission to hospital for complications
Discharge to 8 weeks
Any readmission 51/234 (22%) 31/234 (13%) 0·61 (0·40 to 0·91)‡
Total number of readmissions 71 38 0·54 (0·34 to 0·85)†
Discharge to 6 months
Any readmission 73/223 (32%) 58/227 (26%) 0·78 (0·58 to 1·04)‡
Total number of readmissions  130 84 0·64 (0·44 to 0·92)†
Safety outcomes to 6 months§
SAEs and SUSARs 23/240 (10%) 22/240 (9%) 0·96 (0·55 to 1·67)‡
Adverse reaction to trial therapy 5/240 (2%) 11/240 (5%) 2·20 (0·78 to 6·24)‡
Development of perioperative AKI 13/122 (11%) 11/137 (8%) 0·75 (0·35 to 1·62)‡
Data are mean (SD), n/N (%), n, median (IQR), range, or treatment effect (95% CI). LBT=large blood transfusion, 
defined as 4 or more units of blood transfused in a single transfusion episode (there were 9 LBTs in total). 
CD=Clavien–Dindo. ICU=intensive care unit. MFI=Multidimensional Fatigue Inventory. EQ-5D-5L=European Quality 
of Life: 5 Dimensions 5 Levels. SAE=serious adverse event. SUSAR=suspected unexpected serious adverse event. 
AKI=acute kidney injury. *Total number of units of blood or blood products transfused. Treatment effect is either 
difference in mean or rate ratio (†) or risk ratio (‡). §Safety outcomes measured in the safety population.
Table 4: PREVENTT secondary and safety endpoints
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Discussion
The use of intravenous iron in patients with anaemia 
before major open elective abdominal surgery increased 
haemoglobin concentrations before surgery but did not 
reduce the frequency of blood transfusion or mortality in 
the perioperative period relative to placebo. There was 
no reduction in the risk of postoperative in-hospital 
complications or length of hospital stay, and no benefits 
to quality of life. However, there was a reduced risk of 
readmission to hospital for complications in those 
patients who received intravenous iron.
PREVENTT reduces the uncertainty created by two 
previous small trials on the use of preoperative intra-
venous iron. The IVICA trial from Nottingham, UK, 
looked at 116 patients with anaemia undergoing colorectal 
cancer surgery and found that intravenous iron had no 
effect on blood transfusion use,18 whereas a smaller trial 
of 72 patients in Australia found that intravenous iron 
for patients with iron deficiency anaemia (ferritin 
<300 µg/L, transferrin saturation <25%) did reduce peri-
operative blood transfusion (12% vs 31%).19 PREVENTT 
suggests that preoperative intravenous iron has no 
significant effect on blood transfusion use in all patients 
with anaemia before major surgery.
Our findings are consistent with the existing evidence 
on iron therapy in non-cardiac patients. Trials of inter-
ventions to reverse anaemia, either with iron therapy 
or more liberal transfusion thresholds, have failed to 
show important clinical benefits,20,21 despite observational 
evidence that anaemia is associated with poorer out-
comes. This fact implies that treatments directed to the 
underlying causes of anaemia might be required to 
improve outcomes in this high-risk population.
The trial has several strengths, including allocation 
concealment, double-blinding, placebo control, high 
levels of adherence to the trial intervention (481/487), 
and low levels of attrition, with 474 of 487 participants 
providing data for the primary intention-to-treat analyses. 
There was no difference between the results of the per-
protocol and intention-to-treat analyses or between the 
predefined subgroups, suggesting that non-adherence 
with other components of the protocol was unlikely to 
have influenced the trial result. The study included 
patients with a range of anaemia profiles including mild 
anaemia. These strengths, along with the broad inclusion 
criteria, clear documentation of process, and absence of 
effectiveness across a range of primary and secondary 
outcomes, support the validity and generalisability of 
the trial results.
One limitation was that preoperative iron deficiency 
was not specifically defined as an inclusion criterion 
although a predefined subgroup analysis was performed 
for those patients with a ferritin less than 100 ng/mL and 
trans ferrin saturations less than 20% in line with current 
guidelines for preoperative iron deficiency,13 of whom 
57% had a ferritin less than 100 ng/mL and 76% had 
transferrin saturations less than 20% at inclusion and 
randomisation to the trial. There was no evidence of 
interaction between treatment in these predefined 
subgroups for the coprimary endpoints of the study.
The trial data suggest that there is no mortality or 
blood transfusion benefits to treating patients with a 
single 1000 mg dose of ferric carboxymaltose in the 
immediate preoperative period. Preoperative anaemia 
management is challenging in many health systems 
where preassessment is often carried out days before 
surgery, particularly for patients who have cancer for 
whom surgery is a priority, highlighted by recruitment 
to this trial where inclusion was a minimum of 10 days 
before surgery. The efficacy of intravenous iron was 
lower than expected with a minority of patients having 
their anaemia corrected before their date of surgery. The 
causal mechanism behind anaemia in the preoperative 
setting might require treatment with concurrent erythro-
poietin as seen in cardiac surgery.22 Erythropoietin is not 
licensed in such patients in the UK, but erythropoietin 
and intravenous iron has been recommended for 
anaemia in patients before orthopaedic surgery.12 Our 
findings have several important clinical implications. 
The treatment effect on mean haemoglobin values was 
higher after surgery than in the preoperative setting, 
despite no differences in type of surgery, bleeding, or 
transfusion volumes between the groups. The effect of 
preoperative intravenous iron and increased post-
operative haemoglobin levels associated with reduced 
readmission to hospital for surgical complications 
merits further investigation. This effect might reflect 
an underlying mechanism of functional or absolute 
iron deficiency and anaemia of chronic disease with 
inflammation, and subsequent stimulus of blood loss at 
operation. Clinically, this finding raises the possibility 
that postoperative intravenous iron, before discharge 
from the hospital, might be effective at boosting 
haemoglobin levels in surgical patients during their 
recovery period. Postoperative intravenous iron would 
be easier and less expensive than intravenous iron 
preoperatively because the patient would already be in 
the hospital, being nursed and monitored in a hospital 
bed, and likely to have venous access in situ. This 
approach is unlikely, however, to be any more effective 
than preoperative intravenous iron in accruing benefits 
to the primary outcomes measured in our trial.
In conclusion, PREVENTT showed that intravenous 
iron was not superior to placebo when administered 
to patients with anaemia 10–42 days before elective 
major abdominal surgery with respect to reducing blood 
transfusion or death in the perioperative period.
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